Welcome to our dedicated page for Medifast news (Ticker: MED), a resource for investors and traders seeking the latest updates and insights on Medifast stock.
Medifast Inc (MED) provides investors and stakeholders with centralized access to official company announcements and market-moving developments. This resource aggregates all press releases, financial disclosures, and strategic updates from the clinical nutrition leader known for its OPTAVIA® coaching programs and evidence-based weight management solutions.
Users will find chronological updates covering earnings reports, product innovations, leadership changes, and operational milestones. The curated collection serves as both historical record and strategic tool for tracking MED's position in the $250B+ global wellness industry.
Key content categories include quarterly financial results, clinical study publications, partnership announcements, and regulatory filings. All materials are sourced directly from Medifast's investor relations team to ensure accuracy and timeliness.
Bookmark this page for streamlined monitoring of MED's business trajectory, with updates organized to highlight material developments affecting long-term growth in the health solutions sector.
Medifast (NYSE: MED) will announce its fourth quarter and full year financial results on February 21, 2023, after market close. The announcement will be followed by a conference call at 4:30 p.m. ET, featuring CEO Dan Chard and CFO Jim Maloney. Interested parties can listen via the company's website. A telephonic playback will be available from 6:30 p.m. ET on the same day until February 28, 2023. Medifast emphasizes its position as a leader in the $7 billion weight management industry, impacting over 2 million lives through its community of OPTAVIA Coaches.
On December 8, 2022, Medifast (NYSE: MED) announced a quarterly cash dividend of $1.64 per share to stockholders, payable on February 7, 2023, to those on record as of December 20, 2022. The company aims to maintain a consistent dividend program, although future declarations depend on the Board of Directors' discretion based on relevant evaluations. Medifast is a leader in the $7 billion weight management industry, impacting over 2 million lives through its health community, OPTAVIA.
Medifast (NYSE: MED) reported Q3 2022 results, revealing a revenue decline of 5.6% to $390.4 million compared to Q3 2021. Active earning OPTAVIA Coaches increased by 8.5% to 66,200, but average revenue per coach fell by 12.9% to $5,897. Net income decreased to $36.2 million, or $3.27 per diluted share. The company announced a quarterly cash dividend of $1.64 per share and ended the quarter with $69.7 million in cash and no debt. Full-year revenue guidance was revised down to $1.51 billion to $1.59 billion due to inflation and acquisition challenges.
Medifast (NYSE: MED) announced that its OPTA VIA Program was recognized as the #1 Weight Loss Program in the U.S. by revenue for 2021, according to Euromonitor International. The program focuses on holistic health, impacting over two million lives and achieving a revenue increase of 455% over five years, from $501 million in 2018 to $1.526 billion in 2021. Medifast's independent coaches supported over one million clients in the past year. The company will announce its Q3 2022 financial results on November 3, 2022.
Medifast (NYSE: MED) will announce its third quarter financial results for the period ending September 30, 2022 on November 3, 2022, after market close. A conference call to discuss the results will take place at 4:30 p.m. ET on the same day, hosted by CEO Dan Chard and CFO Jim Maloney. Investors can join the call via the company’s website or by telephone. A playback of the call will be available until November 10, 2022. Medifast is recognized as a leader in the U.S. weight management industry, valued at $7 billion.
Medifast (NYSE: MED) has launched the "Healthy Habits For All" curriculum in partnership with WeAreTeachers, aiming to promote health education among students nationwide. Designed for grades K-5, the curriculum focuses on essential health topics such as nutrition, physical activity, and mental well-being. It is accessible to millions of teachers, with a priority on under-resourced communities. Medifast projects the program will reach over 20,000 students in 700 school districts across all 50 states. This initiative aligns with Medifast's commitment to improving public health through education.
Medifast (NYSE: MED) declared a $1.64 quarterly cash dividend, payable on November 8, 2022, to stockholders of record as of September 20, 2022. The company aims to sustain a quarterly dividend program, contingent on its Board of Directors' discretion. Medifast is a leader in the U.S. weight management market, valued at $7 billion, helping over 2 million customers through its OPTAVIA® community. This dividend announcement underscores Medifast's financial health and commitment to returning value to shareholders.
FAQ
What is the current stock price of Medifast (MED)?
What is the market cap of Medifast (MED)?
